Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

Y0001668

Methotrexate for system suitability

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

Methotrexate, (+)-Amethopterin, 4-Amino-10-methylfolic acid, 4-Amino-N10-methylpteroyl-L-glutamic acid, Antifolan, MTX, Methylaminopterin

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C20H22N8O5
Numero CAS:
59-05-2
Peso molecolare:
454.44
Beilstein:
70669
Numero MDL:
MFCD00064370
Codice UNSPSC:
41116107
ID PubChem:
329831530
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

methotrexate

Produttore/marchio commerciale

EDQM

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

CN(Cc1cnc2nc(N)nc(N)c2n1)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O

InChI

1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
FBOZXECLQNJBKD-ZDUSSCGKSA-N

Informazioni sul gene

human ... DHFR(1719)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Methotrexate for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

M1000000

Methotrexate, European Pharmacopoeia (EP) Reference Standard

M1000008

Methotrexate impurity D, European Pharmacopoeia (EP) Reference Standard

Y0000602

Methotrexate for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0000663

Methotrexate impurity C, European Pharmacopoeia (EP) Reference Standard

Y0000664

Methotrexate impurity E, European Pharmacopoeia (EP) Reference Standard

PHR1396

Methotrexate, Pharmaceutical Secondary Standard; Certified Reference Material

1414003

Methotrexate, United States Pharmacopeia (USP) Reference Standard

1413988

R-Methotrexate, United States Pharmacopeia (USP) Reference Standard

1413999

Methotrexate System Suitability Mixture, United States Pharmacopeia (USP) Reference Standard

1414025

Methotrexate Related Compound B, United States Pharmacopeia (USP) Reference Standard

1414036

Methotrexate Related Compound C, United States Pharmacopeia (USP) Reference Standard

1414058

Methotrexate Related Compound E, United States Pharmacopeia (USP) Reference Standard

Pittogrammi

Skull and crossbonesHealth hazard
GHS06,GHS08

Avvertenze

Danger

Indicazioni di pericolo

H301,H341,H360D,H372

Classi di pericolo

Acute Tox. 3 Oral - Muta. 2 - Repr. 1B - STOT RE 1

Organi bersaglio

Liver,Bone marrow

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 2

1 of 2

Methotrexate solution 1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

M-136

Methotrexate solution

Metotrexato powder, BioReagent, suitable for cell culture, ≥98% (HPLC)

Sigma-Aldrich

M8407

Metotrexato

Joshua F Baker et al.
Annals of the rheumatic diseases, 73(11), 1968-1974 (2013-08-02)
To determine if early MRI measures predict X-ray progression at 1 and 2 years in a large RA trial cohort. This study included 256 methotrexate (MTX)-naïve RA patients from a randomised placebo-controlled trial of golimumab (GO-BEFORE). MRIs of wrist and 2nd-5th
Anna-Birgitte Aga et al.
Annals of the rheumatic diseases, 74(2), 381-388 (2013-11-29)
To investigate whether baseline disease activity levels and responses in patients with rheumatoid arthritis (RA) changed during the period 2000-2010. Data were provided by the Norwegian disease-modifying antirheumatic drug (NOR-DMARD) study. Patients with inflammatory joint diseases starting new treatment with
Axel Finckh et al.
Arthritis research & therapy, 16(5), 458-458 (2014-10-16)
Calcium pyrophosphate deposition (CPPD) may cause severe arthropathy, major joint destruction and treatment options are limited. The aim of this study was to test the therapeutic efficacy of methotrexate (MTX) in chronic or recurrent CPPD arthropathy. Patients with CPPD arthropathy
Giovanni L Mancardi et al.
Neurology, 84(10), 981-988 (2015-02-13)
To assess in multiple sclerosis (MS) the effect of intense immunosuppression followed by autologous hematopoietic stem cells transplantation (AHSCT) vs mitoxantrone (MTX) on disease activity measured by MRI. We conducted a multicenter, phase II, randomized trial including patients with secondary
Rongrong Jiang et al.
British journal of pharmacology, 172(4), 1059-1073 (2014-10-10)
Ginsenosides are bioactive saponins derived from Panax notoginseng roots (Sanqi) and ginseng. Here, the molecular mechanisms governing differential pharmacokinetics of 20(S)-protopanaxatriol-type ginsenoside Rg1 , ginsenoside Re and notoginsenoside R1 and 20(S)-protopanaxadiol-type ginsenosides Rb1, Rc and Rd were elucidated. Interactions of
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.